Screening older adults for impaired visual acuity: A review of the evidence for the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 151, Issue 1, 2009, Pages 44-58

  Chou, Roger ^a   Dana, Tracy ^a   Bougatsos, Christina ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN; ZINC;

AGED; BACKACHE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DATA SYNTHESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG FATALITY; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EYE EXAMINATION; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LIGHT REFRACTION; LUNG CANCER; MASS SCREENING; MEDLINE; METHODOLOGY; OBSERVATIONAL STUDY; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REFRACTION ERROR; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SKIN DISCOLORATION; SPECTACLES; STANDARD; STROKE; THROMBOEMBOLISM; TRAUMATIC CATARACT; UROGENITAL TRACT DISEASE; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 67650080804     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-1-200907070-00008     Document Type: Review

References (91)

1. Vitale S, Cotch MF, Sperduto RD. Prevalence of visual impairment in the United States. JAMA. 2006;295:2158-63. [PMID: 16684986]
2. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc. 1998;46:58-64. [PMID: 9434666]
3. Klein BE, Moss SE, Klein R, Lee KE, Cruickshanks KJ. Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. Ophthalmology. 2003;110:644-50. [PMID: 12689880]
4. McGwin G Jr, Chapman V, Owsley C. Visual risk factors for driving difficulty among older drivers. Accid Anal Prev. 2000;32:735-44. [PMID: 10994600]
5. West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci. 1997;38:72-82. [PMID: 9008632]
6. Eye Diseases Prevalence Research Group. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol. 2004;122:495-505. [PMID: 15078666]
7. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-72. [PMID: 15078675]
8. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-85. [PMID: 15078664]
9. U.S. Preventive Services Task Force. Chapter 33: screening for visual impairment. In: Guide to Clinical Preventive Services. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; 1996. Accessed at www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat3.chapter.10062 on 19 May 2009.
10. Chou R, Dana T, Bougatsos C. Screening for visual impairment in older adults: systematic review to update the 1996 U.S. Preventive Services Task Force Recommendation. Prepared by the Oregon Evidence-based Practice Center for the Agency for Healthcare Research and Quality under contract 290-2007-10057-I-EPC3. Evidence synthesis no. 71. AHRQ publication no. 09-05135-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; July 2009. Accessed at www.ahrq.gov/clinic/uspstf/uspstopics.htm on 13 May 2009.
11. Fleming C, Whitlock E, Beil T, Smit B. Primary care screening for ocular hypertension and primary open-angle glaucoma: Evidence synthesis no. 34. Rockville, MD: Agency for Healthcare Research and Quality; March 2005. Accessed at www.ahrq.gov/clinic/uspstf05/glaucoma/glaucsyn.pdf on 13 May 2009.
12. Norris SL, Kansagara D, Bougatsos C, Nygren P, Fu R. Screening for type 2 diabetes mellitus: update of 2003 systematic evidence review for the U.S. Preventive Services Task Force. Evidence synthesis no. 61. Rockville, MD: Agency for Healthcare Research and Quality; June 2008. Accessed at www.ahrq.gov/clinic/uspstf08/type2/type2es.pdf on 13 May 2009.
13. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
14. Whitlock EP, Lin JS, Chou R, Shekelle P, Robinson KA. Using existing systematic reviews in complex systematic reviews. Ann Intern Med. 2008;148:776-82. [PMID: 18490690]
15. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:702-8. [PMID: 15031246]
16. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994;271:703-7. [PMID: 8309035]
17. Eekhof J, De Bock G, Schaapveld K, Springer M. Effects of screening for disorders among the elderly: an intervention study in general practice. Fam Pract. 2000;17:329-33. [PMID: 10934182]
18. Moore AA, Siu A, Partridge JM, Hays RD, Adams J. A randomized trial of office-based screening for common problems in older persons. Am J Med. 1997;102:371-8. [PMID: 9217619]
19. Smeeth L, Fletcher AE, Hanciles S, Evans J, Wormald R. Screening older people for impaired vision in primary care: cluster randomised trial. BMJ. 2003;327:1027. [PMID: 14593039]
20. Cumming RG, Ivers R, Clemson L, Cullen J, Hayes MF, Tanzer M, et al. Improving vision to prevent falls in frail older people: a randomized trial. J Am Geriatr Soc. 2007;55:175-81. [PMID: 17302652]
21. Taylor HR, Vu HT, McCarty CA, Keeffe JE. The need for routine eye examinations. Invest Ophthalmol Vis Sci. 2004;45:2539-42. [PMID: 15277474]
22. Ariyasu RG, Lee PP, Linton KP, LaBree LD, Azen SP, Siu AL. Sensitivity, specificity, and predictive values of screening tests for eye conditions in a clinic-based population. Ophthalmology. 1996;103:1751-60. [PMID: 8942866]
23. McMurdo ME, Baines PS. The detection of visual disability in the elderly. Health Bull (Edinb). 1988;46:327-9. [PMID: 3240947]
24. Eekhof JA, De Bock GH, Schaapveld K, Springer MP. Screening for hearing and visual loss among elderly with questionnaires and tests: which method is the most convincing for action? Scand J Prim Health Care. 2000;18:203-7. [PMID: 11205087]
25. Hiller R, Krueger DE. Validity of a survey question as a measure of visual acuity impairment. Am J Public Health. 1983;73:93-6. [PMID: 6848004]
26. Chu-Ai Teh R, Lim WS, Basri R, Ismail NH. Utility of a patient-response screening question for visual impairment [Letter]. J Am Geriatr Soc. 2006;54:370-2. [PMID: 16460398]
27. Wang F, Tielsch JM, Ford DE, Quigley HA, Whelton PK. Evaluation of screening schemes for eye disease in a primary care setting. Ophthalmic Epidemiol. 1998;5:69-82. [PMID: 9672907]
28. Ivers RQ, Optom B, Macaskill P, Cumming RG, Mitchell P. Sensitivity and specificity of tests to detect eye disease in an older population. Ophthalmology. 2001;108:968-75. [PMID: 11320029]
29. Woods RL, Tregear SJ, Mitchell RA. Screening for ophthalmic disease in older subjects using visual acuity and contrast sensitivity. Ophthalmology. 1998;105:2318-26. [PMID: 9855166]
30. Coleman AL, Yu F, Keeler E, Mangione CM. Treatment of uncorrected refractive error improves vision-specific quality of life. J Am Geriatr Soc. 2006;54:883-90. [PMID: 16776781]
31. Owsley C, McGwin G Jr, Scilley K, Meek GC, Seker D, Dyer A. Effect of refractive error correction on health-related quality of life and depression in older nursing home residents. Arch Ophthalmol. 2007;125:1471-7. [PMID: 17998508]
32. Murray A, Jones L, Milne A, Fraser CM, Lourenco T, Burr J. A systematic review of the safety and efficacy of elective photorefractive surgery for the correction of refractive error. Aberdeen, United Kingdom: Health Services Research Unit, University of Aberdeen; April 2005. Accessed at www.nice.org.uk/nicemedia/pdf/ip/Finalreport%20010605.pdf on 13 May 2009.
33. McDonnell PJ, Mangione C, Lee P, Lindblad AS, Spritzer KL, Berry S, et al. Responsiveness of the National Eye Institute Refractive Error Quality of Life instrument to surgical correction of refractive error. Ophthalmology. 2003;110:2302-9. [PMID: 14644711]
34. Schein OD, Vitale S, Cassard SD, Steinberg EP. Patient outcomes of refractive surgery. The refractive status and vision profile. J Cataract Refract Surg. 2001;27:665-73. [PMID: 11377893]
35. Tahzib NG, Bootsma SJ, Eggink FA, Nabar VA, Nuijts RM. Functional outcomes and patient satisfaction after laser in situ keratomileusis for correction of myopia. J Cataract Refract Surg. 2005;31:1943-51. [PMID: 16338565]
36. Powe NR, Schein OD, Gieser SC, Tielsch JM, Luthra R, Javitt J, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol. 1994;112:239-52. [PMID: 8037792]
37. Lundström M, Stenevi U, Thorburn W. Cataract surgery in the very elderly. J Cataract Refract Surg. 2000;26:408-14. [PMID: 10713238]
38. Owsley C, McGwin G Jr, Scilley K, Meek GC, Seker D, Dyer A. Impact of cataract surgery on health-related quality of life in nursing home residents. Br J Ophthalmol. 2007;91:1359-63. [PMID: 17522143]
39. Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. National study of cataract surgery outcomes. Variation in 4-month postoperative outcomes as reflected in multiple outcome measures. Ophthalmology. 1994;101:1131-40; discussion 1140-1. [PMID: 8008355]
40. Mangione CM, Phillips RS, Lawrence MG, Seddon JM, Orav EJ, Goldman L. Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol. 1994;112:1419-25. [PMID: 7980131]
41. Applegate WB, Miller ST, Elam JT, Freeman JM, Wood TO, Gettlefinger TC. Impact of cataract surgery with lens implantation on vision and physical function in elderly patients. JAMA. 1987;257:1064-6. [PMID: 3806895]
42. McGwin G Jr, Li J, McNeal S, Owsley C. The impact of cataract surgery on depression among older adults. Ophthalmic Epidemiol. 2003;10:303-13. [PMID: 14566631]
43. Harwood RH, Foss AJ, Osborn F, Gregson RM, Zaman A, Masud T. Falls and health status in elderly women following first eye cataract surgery: a randomised controlled trial. Br J Ophthalmol. 2005;89:53-9. [PMID: 15615747]
44. Foss AJ, Harwood RH, Osborn F, Gregson RM, Zaman A, Masud T. Falls and health status in elderly women following second eye cataract surgery: a randomised controlled trial. Age Ageing. 2006;35:66-71. [PMID: 16364936]
45. Owsley C, McGwin G Jr, Sloane M, Wells J, Stalvey BT, Gauthreaux S. Impact of cataract surgery on motor vehicle crash involvement by older adults. JAMA. 2002;288:841-9. [PMID: 12186601]
46. McGwin G Jr, Owsley C, Gauthreaux S. The association between cataract and mortality among older adults. Ophthalmic Epidemiol. 2003;10:107-19. [PMID: 12660859]
47. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-36. [PMID: 11594942]
48. Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2008:CD000253. [PMID: 18253971]
49. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005;219:154-66. [PMID: 15947501]
50. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007:CD004763. [PMID: 17636773]
51. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100:912-8. [PMID: 7046707]
52. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:816-24. [PMID: 1693496]
53. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109:1220-31. [PMID: 1718250]
54. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109:1232-41. [PMID: 1718251]
55. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. Br J Ophthalmol. 1982;66:745-53. [PMID: 6184070]
56. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2003;7:v-vi, 1-98. [PMID: 12709292]
57. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007:CD002030. [PMID: 17636693]
58. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-57. [PMID: 15824216]
59. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-45. [PMID: 10532441]
60. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology. 2001;108:841-52. [PMID: 11320011]
61. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an openlabel extension of 2 randomized clinical trials - TAP Report no. 5. Arch Ophthalmol. 2002;120:1307-14. [PMID: 12365909]
62. Kaiser PK; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-42. [PMID: 16538452]
63. Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008:CD005139. [PMID: 18425911]
64. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-16. [PMID: 15625332]
65. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248. [PMID: 18222192]
66. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. [PMID: 17021318]
67. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125:1460-9. [PMID: 17998507]
68. Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age-related macular degeneration: results from the VISION study. Eye. 2008;22:792-8. [PMID: 17585313]
69. Lord SR, Dayhew J, Howland A. Multifocal glasses impair edge-contrast sensitivity and depth perception and increase the risk of falls in older people. J Am Geriatr Soc. 2002;50:1760-6. [PMID: 12410892]
70. Cheng KH, Leung SL, Hoekman HW, Beekhuis WH, Mulder PG, Geerards AJ, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet. 1999;354:181-5. [PMID: 10421298]
71. Nilsson SE, Montan PG. The annualized incidence of contact lens induced keratitis in Sweden and its relation to lens type and wear schedule: results of a 3-month prospective study. CLAO J. 1994;20:225-30. [PMID: 7820916]
72. Schein OD, McNally JJ, Katz J, Chalmers RL, Tielsch JM, Alfonso E, et al. The incidence of microbial keratitis among wearers of a 30-day silicone hydrogel extended-wear contact lens. Ophthalmology. 2005;112:2172-9. [PMID: 16325711]
73. Chalmers RL, McNally JJ, Schein OD, Katz J, Tielsch JM, Alfonso E, et al. Risk factors for corneal infiltrates with continuous wear of contact lenses. Optom Vis Sci. 2007;84:573-9. [PMID: 17632304]
74. Schaumberg DA, Dana MR, Christen WG, Glynn RJ. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology. 1998;105:1213-21. [PMID: 9663224]
75. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123:613-20. [PMID: 15883279]
76. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119:1439-52. [PMID: 11594943]
77. Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. J Urol. 2007;177:639-43. [PMID: 17222649]
78. Kaiser HJ, Flammer J, Stümpfig D, Hendrickson P. Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica. 1995;209:302-5. [PMID: 8751336]
79. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75:216-30. [PMID: 15117055]
80. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113:992-1001.e6. [PMID: 16647134]
81. Avery RL, Ho AC. Good news for anti-VEGF therapy. Accessed at www.retinatoday.com/issues/0308/0308-01.php on 7 May 2009.
82. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338-47. [PMID: 15769967]
83. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-5. [PMID: 8602180]
84. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-35. [PMID: 8127329]
85. Lee AG. Community screening for visual impairment in older people. Community screening for visual impairment in the elderly. J Am Geriatr Soc. 2001;49:673-5. [PMID: 11380765]
86. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2006.
87. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol. 1991;44:1271-8. [PMID: 1834807]
88. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683-96. [PMID: 15059708]
89. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: twoyear results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-60. [PMID: 11336929]
90. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-57. [PMID: 15824216]
91. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, et al; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-52. [PMID: 17270674]